1-5 of 5
Robert J. Spiegel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of α2-Interferon plus Doxorubicin in Patients with Solid Tumors

Free
Gisele A. Sarosy, Thomas D. Brown, Daniel D. Von Hoff, Robert J. Spiegel, James P. Golando, Kenneth L. Beougher, John G. Kuhn, Daniel L. Kisner
Journal: Cancer Research
Cancer Res (1986) 46 (10): 5368–5371.
Published: 01 October 1986
View articletitled, Phase I Study of α2-Interferon plus Doxorubicin in Patients with Solid Tumors
Open the PDF for Phase I Study of α2-Interferon plus Doxorubicin in Patients with Solid Tumors in another window
Journal Articles

Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Free
Jonathan S. Berek, Neville F. Hacker, Alan Lichtenstein, Tyler Jung, Celsa Spina, Reba M. Knox, Jeanine Brady, Teri Greene, Lupe M. Ettinger, Leo D. Lagasse, Eric M. Bonnem, Robert J. Spiegel, Jacob Zighelboim
Journal: Cancer Research
Cancer Res (1985) 45 (9): 4447–4453.
Published: 01 September 1985
View articletitled, Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Open the PDF for Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study in another window
Journal Articles

Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule

Free
Robert J. Spiegel, Ronald H. Blum, Mark Levin, Carolina A. Pinto, James C. Wernz, James L. Speyer, Kim S. Hoffman, Franco M. Muggia
Journal: Cancer Research
Cancer Res (1982) 42 (1): 354–358.
Published: 01 January 1982
View articletitled, Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule
Open the PDF for Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule in another window
Journal Articles

Correspondence re: R. J. Spiegel, I. T. Magrath, and J. A. Shutta. Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells. Cancer Res., 41: 452–458, 1981: On the Lipid Fluidity of Malignant Lymphoid Cell Membranes

Free
Robert J. Spiegel, Ian T. Magrath, John A. Shutta
Journal: Cancer Research
Cancer Res (1981) 41 (9_Part_1): 3670–3671.
Published: 01 September 1981
View articletitled, Correspondence re: R. J. Spiegel, I. T. Magrath, and J. A. Shutta. Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells. Cancer Res., 41: 452–458, 1981: On the Lipid Fluidity of Malignant Lymphoid Cell Membranes
Open the PDF for Correspondence re: R. J. Spiegel, I. T. Magrath, and J. A. Shutta. Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells. Cancer Res., 41: 452–458, 1981: On the Lipid Fluidity of Malignant Lymphoid Cell Membranes in another window
Journal Articles

Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells

Free
Robert J. Spiegel, Ian T. Magrath, John A. Shutta
Journal: Cancer Research
Cancer Res (1981) 41 (2): 452–458.
Published: 01 February 1981
View articletitled, Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells
Open the PDF for Role of Cytoplasmic Lipids in Altering Diphenylhexatriene Fluorescence Polarization in Malignant Cells in another window